Predictive and prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer
The standard of care in locally advanced rectal cancer is neoadjuvant chemoradiation
(nCRT) followed by radical surgery. Response to nCRT varies among patients and …
(nCRT) followed by radical surgery. Response to nCRT varies among patients and …
The current value of determining the mismatch repair status of colorectal cancer: a rationale for routine testing
E Ryan, K Sheahan, B Creavin, HM Mohan… - Critical reviews in …, 2017 - Elsevier
Colorectal Cancer (CRC) is the third most prevalent cancer in men and women. Up to 15%
of CRCs display microsatellite instability (MSI). MSI is reflective of a deficient mismatch …
of CRCs display microsatellite instability (MSI). MSI is reflective of a deficient mismatch …
Integrative molecular characterization of resistance to neoadjuvant chemoradiation in rectal cancer
SC Kamran, JK Lennerz, CA Margolis, D Liu… - Clinical Cancer …, 2019 - AACR
Purpose: Molecular properties associated with complete response or acquired resistance to
concurrent chemotherapy and radiotherapy (CRT) are incompletely characterized …
concurrent chemotherapy and radiotherapy (CRT) are incompletely characterized …
Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer
J Garcia-Aguilar, Z Chen, DD Smith, W Li… - Annals of …, 2011 - journals.lww.com
Objective: To identify a biomarker profile associated with tumor response to chemoradiation
(CRT) in locally advanced rectal cancer. Background: Rectal cancer response to …
(CRT) in locally advanced rectal cancer. Background: Rectal cancer response to …
DNA mismatch repair deficiency in rectal cancer: benchmarking its impact on prognosis, neoadjuvant response prediction, and clinical cancer genetics
N De Rosa, MA Rodriguez-Bigas, GJ Chang… - Journal of Clinical …, 2016 - ascopubs.org
Purpose DNA mismatch repair deficiency (dMMR) hallmarks consensus molecular subtype
1 of colorectal cancer. It is being routinely tested, but little is known about dMMR rectal …
1 of colorectal cancer. It is being routinely tested, but little is known about dMMR rectal …
Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy
E De Mattia, E Cecchin, G Toffoli - Drug Resistance Updates, 2015 - Elsevier
Colorectal cancer (CRC) represents one of the most common malignancies and is major
cause of cancer-related deaths worldwide. A great improvement in response rate and …
cause of cancer-related deaths worldwide. A great improvement in response rate and …
Pharmaco‐metabolomics: an emerging “omics” tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets
G Corona, F Rizzolio, A Giordano… - Journal of cellular …, 2012 - Wiley Online Library
In the post‐genomics era, metabolomics represents a new “omics” approach that in the last
decade has received increased attention in the field of oncology. Metabolomics is based on …
decade has received increased attention in the field of oncology. Metabolomics is based on …
Gene and microRNA expression are predictive of tumor response in rectal adenocarcinoma patients treated with preoperative chemoradiotherapy
C Millino, I Maretto, B Pacchioni… - Journal of cellular …, 2017 - Wiley Online Library
Preoperative chemoradiotherapy (pCRT) followed by surgery is the standard treatment for
locally advanced rectal cancer (LARC). However, tumor response to pCRT is not uniform …
locally advanced rectal cancer (LARC). However, tumor response to pCRT is not uniform …
A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients
M Agostini, A Zangrando, C Pastrello… - Cancer biology & …, 2015 - Taylor & Francis
Preoperative chemoradiotherapy is widely used to improve local control of disease,
sphincter preservation and to improve survival in patients with locally advanced rectal …
sphincter preservation and to improve survival in patients with locally advanced rectal …
Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment
E De Mattia, G Toffoli, J Polesel… - Pharmacogenetics …, 2013 - journals.lww.com
Objective Membrane transporters are widely recognized as important determinants of drug
disposition and response, generating increasing interest on the pharmacological …
disposition and response, generating increasing interest on the pharmacological …